安罗替尼二线治疗晚期非小细胞肺癌的临床效果

Clinical effect of Amlotinib in second-line treatment of advanced non-small cell lung cancer

目的观察安罗替尼二线治疗晚期非小细胞肺癌的临床效果和毒副反应。方法选取2019年1月~2020年3月潮州市人民医院收治的52例晚期非小细胞肺癌患者作为研究对象,经一线化疗进展后,按自愿原则将其分为化疗组(32例)和安罗替尼组(20例)。化疗组患者采用紫杉醇联合顺铂治疗,安罗替尼组患者口服安罗替尼胶囊治疗。比较两组患者的近期疗效及毒副反应发生情况。结果两组患者的客观有效率和疾病控制率比较,差异均无统计学意义(P>0.05)。安罗替尼组患者的食欲不振及胃肠道反应发生率低于化疗组,差异有统计学意义(P<0.05);两组患者的出血、高血压、骨髓抑制、手足综合征、口腔溃疡、肝肾功能损伤、乏力发生率比较,差异均无统计学意义(P>0.05)。结论安罗替尼作为二线方案治疗晚期非小细胞患者的临床效果与化疗相近,且不良反应较少。

Objective To observe the clinical effect and toxicity of Amlotinib in second-line treatment of advanced non-small cell lung cancer.Methods A total of 52 patients with advanced non-small cell lung cancer admitted to People′s Hospital of Chaozhou City from January 2019 to March 2020 were selected as the research objects.After progression of first-line chemotherapy,the patients were divided into chemotherapy group(32 cases)and Amlotinib group(20 cases)on a voluntary basis.Patients in the chemotherapy group were treated with Paclitaxel combined with Cisplatin,and patients in the Amlotinib group were treated with Amlotinib Capsules orally.The short-term efficacy and the occurrence of toxic and side effects were compared between the two groups.Results There were no statistically significant differences in objective effective rate and disease control rate between the two groups(P>0.05).The incidence of anorexia and gastrointestinal reactions in the Amlotinib group were lower than those in the chemotherapy group,and the differences were statistically significant(P<0.05).There were no statistically significant differences in the incidence rates of bleeding,hypertension,myelosuppression,hand-foot syndrome,oral ulcer,liver and kidney function injury and fatigue between the two groups(P>0.05).Conclusion The clinical effect of Amlotinib as a second-line regimen in advanced non-small cell patients is similar to that of chemotherapy,and the adverse reactions are fewer.